GlassScriptPhysician profile
Chung Trinh
NPI 1689426389
$1,738.12
in general payments reported to CMS, 2019-2025
15 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $442 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $332.26 | 2024-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $307.94 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.70 | 2024-2025 | Caplyta |
| Lundbeck LLC | $187.01 | 2024-2025 | Rexulti |
| Corium, LLC | $152.28 | 2024-2025 | Azstarys |
| Vertical Pharmaceuticals, LLC | $122.57 | 2024-2025 | Relexxii |
| Supernus Pharmaceuticals, INC. | $71.18 | 2024-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $61.93 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $61.21 | 2025 | Fanapt |
| Neurocrine Biosciences, INC. | $57.63 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $29.99 | 2024-2025 | Trintellix |
| Harmony Biosciences LLC | $19.49 | 2025 | |
| Abbvie INC. | $17.28 | 2025 | |
| Ironshore Pharmaceuticals INC. | $16.51 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $16.14 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chung Trinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.